Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
University of Arizona
Pfizer
Sumitomo Pharma America, Inc.
Dartmouth-Hitchcock Medical Center
Memorial Sloan Kettering Cancer Center
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals
University of Rochester
Medical College of Wisconsin
Medigene AG
Icahn School of Medicine at Mount Sinai
Bellicum Pharmaceuticals
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
Celgene
University of Wisconsin, Madison
Celgene
University College, London
University of Maryland, Baltimore
University of Pittsburgh
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
University of California, San Francisco
California Cancer Consortium
Massachusetts General Hospital
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Yale University
Alliance for Clinical Trials in Oncology
Massachusetts General Hospital
City of Hope Medical Center
National Cancer Institute (NCI)
4SC AG
Cellerant Therapeutics
Indiana University
Indiana University
Duke University
University of Chicago
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
University of California, San Francisco
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Alaunos Therapeutics